<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595438</url>
  </required_header>
  <id_info>
    <org_study_id>D4280C00002</org_study_id>
    <secondary_id>2011-005721-43</secondary_id>
    <nct_id>NCT01595438</nct_id>
  </id_info>
  <brief_title>Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)</brief_title>
  <official_title>A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Croatia: Ministry of Health and Social Care</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>India: Ministry of Health</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to
      Doripenem for treating hospitalized patients with complicated urinary tract infections,
      including acute pyelonephritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group,
      Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime
      Avibactam (CAZ-AVI, formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy
      in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis,
      With a Gram Negative Pathogen in Hospitalized Adults
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test</measure>
    <time_frame>At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with symptomatic resolution (or return to premorbid state) of UTI-specific symptoms except flank pain (frequency/urgency/dysuria/suprapubic pain) with resolution of or improvement in flank pain based on the patient-reported symptom assessment response at the Day 5 visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with both a favorable per patient microbiological response and symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/dysuria/suprapubic pain/flank pain) based on the patient-reported symptom assessment response at the TOC visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per patient microbiological response at TOC. The primary efficacy outcome variable for ROW is the proportion of patients with a favorable per-patient microbiological response at the TOC visit in the mMITT analysis set.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at LFU (mMITT Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per patient microbiological response at LFU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per patient microbiological response at TOC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per patient microbiological response at LFU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per patient microbiological response at TOC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a favorable per patient microbiological response at LFU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at TOC (mMITT Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at LFU (mMITT Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)</measure>
    <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first defervescence while on IV study therapy in patients in the mMITT analysis set who have fever at study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)</measure>
    <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first defervescence while on IV study therapy in patients in the ME at TOC analysis set who have fever at study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)</measure>
    <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first defervescence while on IV study therapy in patients in the Extended ME at TOC analysis set who have fever at study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)</measure>
    <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first defervescence while on IV study therapy in patients in the CE at TOC analysis set who have fever at study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)</measure>
    <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)</measure>
    <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)</measure>
    <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)</measure>
    <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set for blood only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the mMITT analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the Extended ME at TOC analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the ME at TOC analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the mMITT analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the Extended ME at TOC analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)</measure>
    <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the ME at TOC analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)</measure>
    <time_frame>within 15 minutes before/after dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)</measure>
    <time_frame>Between 30 to 90 minutes after dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)</measure>
    <time_frame>Between 300 to 360 minutes after dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)</measure>
    <time_frame>within 15 minutes before/after dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)</measure>
    <time_frame>Between 30 to 90 minutes after dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)</measure>
    <time_frame>Between 300 to 360 minutes after dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">598</enrollment>
  <condition>Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Ceftazidime - Avibactam ( CAZ-AVI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doripenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime - Avibactam ( CAZ-AVI)</intervention_name>
    <description>Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes</description>
    <arm_group_label>Ceftazidime - Avibactam ( CAZ-AVI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doripenem</intervention_name>
    <description>500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes</description>
    <arm_group_label>Doripenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)</intervention_name>
    <description>Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement</description>
    <arm_group_label>Ceftazidime - Avibactam ( CAZ-AVI)</arm_group_label>
    <arm_group_label>Doripenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)</intervention_name>
    <description>Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement</description>
    <arm_group_label>Ceftazidime - Avibactam ( CAZ-AVI)</arm_group_label>
    <arm_group_label>Doripenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 90 years of age inclusive

          -  Female patients can participate if they are surgically sterile or completed menopause
             or females capable of having children and agree not to attempt pregnancy while
             receiving IV study therapy and for a period of 7 days after

          -  Has pyuria with &gt;/= 10 WBCs (white blood cell) and has a positive urine culture
             within 48 hours of enrollment containing &gt;/=10 to the fifth CFU (colony forming unit
             ) /ml of a recognized uropathogen known to be susceptible to IV study therapy
             (CAZ-AVI and doripenem)

          -  Demonstrates either acute pyelonephritis or complicated lower UTI without
             pyelonephritis.

        Exclusion Criteria:

          -  Urine pathogen is a Gram-positive pathogen or a uropathogen resistant to CAZ-AVI or
             doripenem

          -  Patient's urine culture at study entry isolates more than 2 microorganisms regardless
             of colony count or patient has a confirmed fungal UTI

          -  Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant

          -  Patient is immunocompromised

          -  Patient is considered unlikely to survive the 6- to 8-week study period or has a
             rapidly progressive or terminal illness including septic shock which is associated
             with a high risk of mortality
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Newell, MBBS, MRCP</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Campinas/SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São José do Rio Preto - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vila Clementino</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyjov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagykanizsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshigaya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokushima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ueda-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utsunomiya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Inowrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Diyarbakir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mykolaiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>India</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 8, 2016</lastchanged_date>
  <firstreceived_date>April 27, 2012</firstreceived_date>
  <firstreceived_results_date>October 28, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ceftazidime, Avibactam, Doripenem, Ciprofloxacin, sulfamethoxazole/trimethoprim, Anti-Infective Agents, Complicated Urinary Tract Infection,Acute Pyelonephritis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim-Sulfamethoxazole Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The results presented in these forms represent the combined data base of the two identical protocols D4280C00002 and D4280C00004. The protocol D4280C00002 has a total of 522 randomized patients and the protocol D4280C00004 has a total of 511 randomized patients which adds up to a combined total of 1033 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CAZ-AVI</title>
          <description>Ceftazidime-avibactam treatment group</description>
        </group>
        <group group_id="P2">
          <title>Doripenem</title>
          <description>Doripenem treatment group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="516"/>
                <participants group_id="P2" count="517"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="473"/>
                <participants group_id="P2" count="476"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>CAZ-AVI</title>
          <description>Ceftazidime-avibactam treatment group</description>
        </group>
        <group group_id="B2">
          <title>Doripenem</title>
          <description>Doripenem treatment group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="511"/>
                <measurement group_id="B2" value="509"/>
                <measurement group_id="B3" value="1020"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.6" spread="19.76" lower_limit="18" upper_limit="89"/>
                <measurement group_id="B2" value="52.3" spread="18.83" lower_limit="18" upper_limit="86"/>
                <measurement group_id="B3" value="52.0" spread="19.29" lower_limit="18" upper_limit="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18-45</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="192"/>
                <measurement group_id="B2" value="172"/>
                <measurement group_id="B3" value="364"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>46-64</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="162"/>
                <measurement group_id="B2" value="177"/>
                <measurement group_id="B3" value="339"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>65-74</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
                <measurement group_id="B2" value="98"/>
                <measurement group_id="B3" value="177"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>75-90</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="78"/>
                <measurement group_id="B2" value="62"/>
                <measurement group_id="B3" value="140"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="349"/>
                <measurement group_id="B2" value="357"/>
                <measurement group_id="B3" value="706"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="162"/>
                <measurement group_id="B2" value="152"/>
                <measurement group_id="B3" value="314"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian Or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="85"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black Or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="75"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="421"/>
                <measurement group_id="B2" value="426"/>
                <measurement group_id="B3" value="847"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test</title>
        <description>Number of patients with symptomatic resolution (or return to premorbid state) of UTI-specific symptoms except flank pain (frequency/urgency/dysuria/suprapubic pain) with resolution of or improvement in flank pain based on the patient-reported symptom assessment response at the Day 5 visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)).</description>
        <time_frame>At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test</title>
            <description>Number of patients with symptomatic resolution (or return to premorbid state) of UTI-specific symptoms except flank pain (frequency/urgency/dysuria/suprapubic pain) with resolution of or improvement in flank pain based on the patient-reported symptom assessment response at the Day 5 visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)).</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Symptomatic resolution</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="276"/>
                  <measurement group_id="O2" value="276"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Symptom persistence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="124"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Difference (CAZ-AVI treatment group minus Doripenem treatment group) of symptomatic resolution rates ≤ non-inferiority margin</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>-12.5%</non_inferiority_desc>
            <param_type>Difference of symp resolution rates</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>10.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test</title>
        <description>Number of patients with both a favorable per patient microbiological response and symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/dysuria/suprapubic pain/flank pain) based on the patient-reported symptom assessment response at the TOC visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)).</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test</title>
            <description>Number of patients with both a favorable per patient microbiological response and symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/dysuria/suprapubic pain/flank pain) based on the patient-reported symptom assessment response at the TOC visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)).</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                  <measurement group_id="O2" value="109"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable combined response rates ≤ non-inferiority margin</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>-12.5%</non_inferiority_desc>
            <param_type>Diff of favorable combined resp rates</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>13.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test</title>
        <description>Number of patients with a favorable per patient microbiological response at TOC. The primary efficacy outcome variable for ROW is the proportion of patients with a favorable per-patient microbiological response at the TOC visit in the mMITT analysis set.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test</title>
            <description>Number of patients with a favorable per patient microbiological response at TOC. The primary efficacy outcome variable for ROW is the proportion of patients with a favorable per-patient microbiological response at the TOC visit in the mMITT analysis set.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                  <measurement group_id="O2" value="296"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates ≤ non-inferiority margin</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>-12.5%</non_inferiority_desc>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>12.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)</title>
        <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)</title>
            <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="374"/>
                  <measurement group_id="O2" value="395"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.70</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at LFU (mMITT Analysis Set)</title>
        <description>Number of patients with a favorable per patient microbiological response at LFU</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at LFU (mMITT Analysis Set)</title>
            <description>Number of patients with a favorable per patient microbiological response at LFU</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="268"/>
                  <measurement group_id="O2" value="254"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>13.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)</title>
        <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at EOT (IV) (ME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="325"/>
                  <measurement group_id="O2" value="361"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)</title>
            <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="324"/>
                  <measurement group_id="O2" value="359"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)</title>
        <description>Number of patients with a favorable per patient microbiological response at TOC</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC (ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)</title>
            <description>Number of patients with a favorable per patient microbiological response at TOC</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="241"/>
                  <measurement group_id="O2" value="225"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="73"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.27</ci_lower_limit>
            <ci_upper_limit>15.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)</title>
        <description>Number of patients with a favorable per patient microbiological response at LFU</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at LFU (ME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="245"/>
                  <measurement group_id="O2" value="262"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)</title>
            <description>Number of patients with a favorable per patient microbiological response at LFU</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="182"/>
                  <measurement group_id="O2" value="166"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>10.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>18.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)</title>
        <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at EOT (IV) (EME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="336"/>
                  <measurement group_id="O2" value="371"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)</title>
            <description>Number of patients with a favorable per-patient microbiological response at EOT (IV)</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="335"/>
                  <measurement group_id="O2" value="369"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)</title>
        <description>Number of patients with a favorable per patient microbiological response at TOC</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC (Extended ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)</title>
            <description>Number of patients with a favorable per patient microbiological response at TOC</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="243"/>
                  <measurement group_id="O2" value="236"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>13.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)</title>
        <description>Number of patients with a favorable per patient microbiological response at LFU</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at LFU (Extended ME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="251"/>
                  <measurement group_id="O2" value="272"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)</title>
            <description>Number of patients with a favorable per patient microbiological response at LFU</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>9.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>17.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)</title>
        <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)</title>
            <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="378"/>
                  <measurement group_id="O2" value="407"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.07</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at TOC (mMITT Analysis Set)</title>
        <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at TOC (mMITT Analysis Set)</title>
            <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="355"/>
                  <measurement group_id="O2" value="377"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.23</ci_lower_limit>
            <ci_upper_limit>4.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at LFU (mMITT Analysis Set)</title>
        <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at LFU (mMITT Analysis Set)</title>
            <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="335"/>
                  <measurement group_id="O2" value="350"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.71</ci_lower_limit>
            <ci_upper_limit>6.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)</title>
        <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at EOT (IV) (ME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="325"/>
                  <measurement group_id="O2" value="361"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)</title>
            <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="318"/>
                  <measurement group_id="O2" value="358"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)</title>
        <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC (ME at TOC )</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)</title>
            <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="277"/>
                  <measurement group_id="O2" value="285"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.03</ci_lower_limit>
            <ci_upper_limit>4.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)</title>
        <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at LFU (ME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="245"/>
                  <measurement group_id="O2" value="262"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)</title>
            <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="236"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>7.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)</title>
        <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at EOT (IV) (Extended ME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="336"/>
                  <measurement group_id="O2" value="371"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)</title>
            <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="327"/>
                  <measurement group_id="O2" value="368"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.30</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)</title>
        <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC (Extended ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)</title>
            <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="283"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)</title>
        <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at LFU (Extended ME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="251"/>
                  <measurement group_id="O2" value="272"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)</title>
            <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="232"/>
                  <measurement group_id="O2" value="246"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.94</ci_lower_limit>
            <ci_upper_limit>6.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)</title>
        <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Clinically evaluable analysis set at EOT (IV) (CE at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="350"/>
                  <measurement group_id="O2" value="391"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)</title>
            <description>Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="346"/>
                  <measurement group_id="O2" value="387"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.99</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)</title>
        <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Clinically evaluable analysis set at TOC (CE at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="297"/>
                  <measurement group_id="O2" value="330"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)</title>
            <description>Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="289"/>
                  <measurement group_id="O2" value="309"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>7.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)</title>
        <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Clinically evaluable analysis set at LFU (CE at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="254"/>
                  <measurement group_id="O2" value="287"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)</title>
            <description>Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient’s clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient’s clinical response.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="235"/>
                  <measurement group_id="O2" value="254"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clinical cure rates</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>9.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)</title>
        <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)</title>
            <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All patients - Clinical cure (n=75, 84)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Escherichia coli patients - Clin cure (n=36, 37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae patients-Clin cure(n=18,30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa patients- Clin cure(n=7,6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae patients-Clin cure(n=7,6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis patients - Clin cure (n=2, 5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates in All patients with a ceftazidime-resistant Gram-negative pathogen</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clin cure rates in All patients</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)</title>
        <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC(ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)</title>
            <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All patients - Clinical cure (n=48, 57)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Escherichia coli patients-Clin cure (n=23,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae patients-Clin cure(n=14, 22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa patients-Clin cure(n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae patients-Clin cure(n=5,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis patients - Clin cure (n=0, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates in All patients with a ceftazidime-resistant Gram-negative pathogen</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clin cure rates in All patients</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)</title>
        <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC(Extended ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)</title>
            <description>Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All patients - Clinical cure (n=51, 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Escherichia coli patients - Clin cure (n=23, 27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae patients-Clin cure(n=15, 23)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa patients-Clin cure(n=3,6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae patients-Clin cure(n=5,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis patients - Clin cure (n=0, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of clinical cure rates in All patients with a ceftazidime-resistant Gram-negative pathogen</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of clin cure rates in All patients</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)</title>
        <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)</title>
            <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.18</ci_lower_limit>
            <ci_upper_limit>16.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)</title>
        <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC(ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)</title>
            <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.03</ci_lower_limit>
            <ci_upper_limit>25.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)</title>
        <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set.</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC(Extended ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)</title>
            <description>Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Favorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unfavorable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference (CAZ-AVI treatment group minus Doripenem treatment group) of favorable response rates</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Diff of favorable response rates</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.91</ci_lower_limit>
            <ci_upper_limit>24.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)</title>
        <description>Time to first defervescence while on IV study therapy in patients in the mMITT analysis set who have fever at study entry.</description>
        <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)</title>
            <description>Time to first defervescence while on IV study therapy in patients in the mMITT analysis set who have fever at study entry.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Number of patients with fever (&gt;38°C) at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="157"/>
                  <measurement group_id="O2" value="150"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number afebrile at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="143"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number censored at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: No difference in time to first defervescence between treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.038</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)</title>
        <description>Time to first defervescence while on IV study therapy in patients in the ME at TOC analysis set who have fever at study entry.</description>
        <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC(ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)</title>
            <description>Time to first defervescence while on IV study therapy in patients in the ME at TOC analysis set who have fever at study entry.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Number of patients with fever (&gt;38°C) at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                  <measurement group_id="O2" value="108"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number afebrile at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number censored at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: No difference in time to first defervescence between treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.129</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)</title>
        <description>Time to first defervescence while on IV study therapy in patients in the Extended ME at TOC analysis set who have fever at study entry.</description>
        <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC(Extended ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)</title>
            <description>Time to first defervescence while on IV study therapy in patients in the Extended ME at TOC analysis set who have fever at study entry.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Number of patients with fever (&gt;38°C) at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                  <measurement group_id="O2" value="111"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number afebrile at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                  <measurement group_id="O2" value="108"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number censored at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: No difference in time to first defervescence between treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.080</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)</title>
        <description>Time to first defervescence while on IV study therapy in patients in the CE at TOC analysis set who have fever at study entry.</description>
        <time_frame>Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Clinically evaluable analysis set at TOC(CE at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="297"/>
                  <measurement group_id="O2" value="330"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)</title>
            <description>Time to first defervescence while on IV study therapy in patients in the CE at TOC analysis set who have fever at study entry.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Number of patients with fever (&gt;38°C) at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="118"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number afebrile at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number censored at the time of the last obs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: No difference in time to first defervescence between treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.155</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set</description>
        <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=292, 306)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="293"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=44, 56)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=17, 13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 11,13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=18, 20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=292, 306)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="229"/>
                  <measurement group_id="O2" value="220"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=44, 56)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=17, 13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 11,13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=18, 20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=292, 306)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="198"/>
                  <measurement group_id="O2" value="189"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=44, 56)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=17, 13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 11,13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=18, 20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set</description>
        <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at EOT (IV) (EME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="336"/>
                  <measurement group_id="O2" value="371"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=250, 274)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="250"/>
                  <measurement group_id="O2" value="274"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=34, 49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=13, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 9, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=18, 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC (EME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=214, 226)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="176"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=32, 42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=14, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 7, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=13, 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at LFU (EME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="251"/>
                  <measurement group_id="O2" value="272"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=179, 198)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="131"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=31, 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=11,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 7, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=12, 16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at EOT (IV) (ME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="325"/>
                  <measurement group_id="O2" value="361"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=249, 270)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="249"/>
                  <measurement group_id="O2" value="270"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=33, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=13,11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 9, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=10, 15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC (ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=214, 221)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="171"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=31, 41)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=14, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 7, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=9, 13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at LFU (ME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="245"/>
                  <measurement group_id="O2" value="262"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=179, 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="127"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=30, 35)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=11,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enterobacter cloacae - Favorable (n= 7, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=8, 13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set for blood only</description>
        <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=32, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=4, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set for blood only</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=32, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=4, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set for blood only</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=32, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=4, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set for blood only</description>
        <time_frame>At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at EOT (IV) (EME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="336"/>
                  <measurement group_id="O2" value="371"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=26, 24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set for blood only</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC (EME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=22, 20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=2, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set for blood only</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at LFU (EME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="251"/>
                  <measurement group_id="O2" value="272"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=19, 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set for blood only</description>
        <time_frame>At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at EOT (IV) (ME at EOT (IV))</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="325"/>
                  <measurement group_id="O2" value="361"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=26, 24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set for blood only</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC (ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=22, 20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=2, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)</title>
        <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set for blood only</description>
        <time_frame>At LFU visit. LFU visit is 45 to 52 days from Randomization.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at LFU (ME at LFU)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="245"/>
                  <measurement group_id="O2" value="262"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)</title>
            <description>Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set for blood only</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Escherichia coli - Favorable (n=19, 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Klebsiella pneumoniae - Favorable (n=2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pseudomonas aeruginosa - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)</title>
        <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the mMITT analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)</title>
            <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the mMITT analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>E. coli (MIC: &lt;=0.008) - Favorable (n=5, 6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.015) - Favorable (n=8, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.03) - Favorable (n=28, 35)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.06) - Favorable (n=123, 139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="111"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.12) - Favorable (n=90, 81)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.25) - Favorable (n=28, 25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.5) - Favorable (n=5, 6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 1) - Favorable (n=3, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 2) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: &gt;32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: &lt;=0.008)-Favorable(n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.06) - Favorable (n=9, 8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: 0.12) -Favorable(n=11, 10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.25) - Favorable (n=4, 10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.5) - Favorable (n=8, 16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 1) - Favorable (n=8, 5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: &gt;32) - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC:&lt;=0.008)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.015)- Favorable (n=1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.03)- Favorable (n=10, 5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.06)- Favorable (n=6,6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.5)- Favorable (n=0,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: &gt;32)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &lt;=0.008)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.12)- Favorable (n= 3,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.25)- Favorable (n= 1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 1)- Favorable (n= 2,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 2)- Favorable (n= 1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 4)- Favorable (n= 2,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 8)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 32)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &gt;32)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &lt;=0.008) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.5) - Favorable (n=0,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 1) - Favorable (n=1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 2) - Favorable (n=5,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 4) - Favorable (n=7,6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 8) - Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 16) - Favorable (n=1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 32) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &gt;32) - Favorable (n=2,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)</title>
        <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the Extended ME at TOC analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC (EME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)</title>
            <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the Extended ME at TOC analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>E. coli (MIC: &lt;=0.008) - Favorable (n=4,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.015) - Favorable (n=5, 6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.03) - Favorable (n=18, 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.06) - Favorable (n=95, 111)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.12) - Favorable (n=68, 54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.25) - Favorable (n=19, 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.5) - Favorable (n=2, 5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 1) - Favorable (n=2, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 2) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: &gt;32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: &lt;=0.008)-Favorable(n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.06) - Favorable (n=5, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: 0.12) -Favorable(n=8, 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.25) - Favorable (n=3, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.5) - Favorable (n=6, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 1) - Favorable (n=6, 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: &gt;32) - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC:&lt;=0.008)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.015)- Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.03)- Favorable (n=9, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.06)- Favorable (n=4,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.5)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: &gt;32)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &lt;=0.008)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.12)- Favorable (n= 1,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.25)- Favorable (n= 0,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 1)- Favorable (n= 1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 2)- Favorable (n= 1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 4)- Favorable (n= 2,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 8)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 32)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &gt;32)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &lt;=0.008) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.5) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 1) - Favorable (n=1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 2) - Favorable (n=4,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 4) - Favorable (n=5,6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 8) - Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 16) - Favorable (n=0,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 32) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &gt;32) - Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)</title>
        <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the ME at TOC analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC (ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)</title>
            <description>Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the ME at TOC analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>E. coli (MIC: &lt;=0.008) - Favorable (n=4,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.015) - Favorable (n=5, 6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.03) - Favorable (n=18, 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.06) - Favorable (n=95, 111)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.12) - Favorable (n=68, 54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.25) - Favorable (n=19, 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.5) - Favorable (n=2, 5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 1) - Favorable (n=2, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 2) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: &gt;32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: &lt;=0.008)-Favorable(n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.06) - Favorable (n=5, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: 0.12) -Favorable(n=8, 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.25) - Favorable (n=3, 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.5) - Favorable (n=6, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 1) - Favorable (n=5, 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: &gt;32) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC:&lt;=0.008)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.015)- Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.03)- Favorable (n=9, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.06)- Favorable (n=4,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.5)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: &gt;32)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &lt;=0.008)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.12)- Favorable (n= 1,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.25)- Favorable (n= 0,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 1)- Favorable (n= 1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 2)- Favorable (n= 1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 4)- Favorable (n= 2,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 8)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 32)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &gt;32)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &lt;=0.008) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.5) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 1) - Favorable (n=1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 2) - Favorable (n=4,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 4) - Favorable (n=3,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 8) - Favorable (n=1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 16) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 32) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &gt;32) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)</title>
        <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the mMITT analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological modified intent to treat analysis set (mMITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="417"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)</title>
            <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the mMITT analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>E. coli (MIC: &lt;=0.008) - Favorable (n=1, 3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.015) - Favorable (n=160, 160)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.03) - Favorable (n=112, 123)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                  <measurement group_id="O2" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.06) - Favorable (n=14, 10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.12) - Favorable (n=3, 3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.25) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.5) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 1) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 2) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: &gt;16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: &lt;=0.008)-Favorable(n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.03)-Favorable (n=22, 27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.06)- Favorable (n=11, 16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: 0.12) -Favorable(n=4,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.5) - Favorable (n=2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 2) - Favorable (n= 0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: &gt;16) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC:&lt;=0.008)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.03)- Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.12)- Favorable (n=6,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.5)- Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: &gt;16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &lt;=0.008)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.015)- Favorable (n= 3,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.03)- Favorable (n= 1,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.06)- Favorable (n= 3, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.12)- Favorable (n= 0, 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.25)- Favorable (n= 0,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.5)- Favorable (n= 4,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 1)- Favorable (n= 0,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 2)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 4)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 8)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &gt;16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &lt;=0.008) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.12) - Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.25) - Favorable (n=2,5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 1) - Favorable (n=1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 2) - Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 4) - Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 8) - Favorable (n=2,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 16) - Favorable (n=2,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &gt;16) - Favorable (n=2,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)</title>
        <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the Extended ME at TOC analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Extended microbiological evaluable analysis set at TOC (EME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="311"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)</title>
            <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the Extended ME at TOC analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>E. coli (MIC: &lt;=0.008) - Favorable (n=1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.015) - Favorable (n=122, 119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.03) - Favorable (n=79, 89)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.06) - Favorable (n=10, 8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.12) - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.25) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.5) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 1) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 2) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: &gt;16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: &lt;=0.008)-Favorable(n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC:0.03) - Favorable (n=15, 23)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.06) - Favorable (n=8, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: 0.12) -Favorable(n=3, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.5) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 2) - Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: &gt;16) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC:&lt;=0.008)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.03)- Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.12)- Favorable (n=4,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.5)- Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: &gt;16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &lt;=0.008)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.015)- Favorable (n= 1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.03)- Favorable (n= 1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.06)- Favorable (n= 2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.12)- Favorable (n= 0,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.25)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.5)- Favorable (n= 3,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 1)- Favorable (n= 0,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 2)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 4)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 8)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &gt;16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &lt;=0.008) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.12) - Favorable (n=1,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.25) - Favorable (n=2,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 1) - Favorable (n=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 2) - Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 4) - Favorable (n=0,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 8) - Favorable (n=1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 16) - Favorable (n=2,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &gt;16) - Favorable (n=1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)</title>
        <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the ME at TOC analysis set</description>
        <time_frame>At TOC visit. TOC visit is 21 to 25 days from Randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological evaluable analysis set at TOC (ME at TOC)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
          <group group_id="O2">
            <title>Doripenem</title>
            <description>Doripenem treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)</title>
            <description>Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the ME at TOC analysis set</description>
            <units>Participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>E. coli (MIC: &lt;=0.008) - Favorable (n=1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.015) - Favorable (n=122, 119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.03) - Favorable (n=79, 89)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.06) - Favorable (n=10, 8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.12) - Favorable (n=1,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.25) - Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 0.5) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 1) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 2) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. coli (MIC: &gt;16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: &lt;=0.008)-Favorable(n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC:0.03) - Favorable (n=15, 23)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.06) - Favorable (n=8, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb.pneumoniae (MIC: 0.12) -Favorable(n=3,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2, 2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 0.5) - Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 2) - Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Kleb. pneumoniae (MIC: &gt;16) - Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC:&lt;=0.008)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.03)- Favorable (n=1, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.12)- Favorable (n=4,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 0.5)- Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Proteus mirabilis (MIC: &gt;16)- Favorable (n=0, 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &lt;=0.008)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.015)- Favorable (n= 1,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.03)- Favorable (n= 1,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.06)- Favorable (n= 2, 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.12)- Favorable (n= 0,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.25)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 0.5)- Favorable (n= 3,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 1)- Favorable (n= 0,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 2)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 4)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 8)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: 16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Entero. cloacae (MIC: &gt;16)- Favorable (n= 0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &lt;=0.008) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.12) - Favorable (n=1,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.25) - Favorable (n=2,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 1) - Favorable (n=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 2) - Favorable (n=1,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 4) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 8) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: 16) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P.aeruginosa (MIC: &gt;16) - Favorable (n=0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)</title>
        <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
        <time_frame>within 15 minutes before/after dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK analysis set (ceftazidime within 15 minutes before/after dose)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="480"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)</title>
            <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
            <units>NG/ML</units>
            <param>Geometric Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65481.2" lower_limit="1260" upper_limit="3190000"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)</title>
        <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
        <time_frame>Between 30 to 90 minutes after dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK analysis set (ceftazidime between 30 to 90 minutes after dose)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="483"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)</title>
            <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
            <units>NG/ML</units>
            <param>Geometric Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47575.1" lower_limit="749" upper_limit="414000"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)</title>
        <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
        <time_frame>Between 300 to 360 minutes after dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK analysis set (ceftazidime between 300 to 360 minutes after dose)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="481"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)</title>
            <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
            <units>NG/ML</units>
            <param>Geometric Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16959.6" lower_limit="156" upper_limit="1640000"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)</title>
        <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
        <time_frame>within 15 minutes before/after dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK analysis set (avibactam within 15 minutes before/after dose)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="489"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)</title>
            <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
            <units>NG/ML</units>
            <param>Geometric Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9307.3" lower_limit="125" upper_limit="1780000"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)</title>
        <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
        <time_frame>Between 30 to 90 minutes after dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK analysis set (avibactam between 30 to 90 minutes after dose)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="490"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)</title>
            <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
            <units>NG/ML</units>
            <param>Geometric Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6587.2" lower_limit="113" upper_limit="105000"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)</title>
        <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
        <time_frame>Between 300 to 360 minutes after dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK analysis set (avibactam between 300 to 360 minutes after dose)</population>
        <group_list>
          <group group_id="O1">
            <title>CAZ-AVI</title>
            <description>Ceftazidime-avibactam treatment group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="488"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)</title>
            <description>Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration.</description>
            <units>NG/ML</units>
            <param>Geometric Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1883.2" lower_limit="26" upper_limit="336000"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The summaries for adverse events are based on the safety analysis set. There is a total of 1020 patients in safety analysis set in both protocol D4280C00002 (i.e. 517 patients) and protocol D4280C00004 (i.e. 503 patients). A total of 13 patients (out of the1033 randomized patients) did not receive any amount of IV study therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>CAZ-AVI</title>
          <description>Ceftazidime-avibactam treatment group</description>
        </group>
        <group group_id="E2">
          <title>Doripenem</title>
          <description>Doripenem treatment group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="511"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Coronary artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="511"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="511"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="511"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="511"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="511"/>
                <counts group_id="E2" events="41" subjects_affected="40" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigator submits the proposed publication and /or presentation to AZAB for review at least 60 days prior to proposed publication and/or presentation. If AZAB, requests in writing, then PI shall withhold publication and/or presentation for an additional 90 days to allow AZAB to protect its intellectual rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gayan Makumburage</name_or_title>
      <organization>AstraZeneca/ PPD</organization>
      <phone>9105588682</phone>
      <email>gayan.makumburage@ppdi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
